Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132043 | 0.88 | MEP1A (0.53) | GSK3BMEP1AMEP1BALDH1A1CYP1A2 | |
| SCHEMBL29393429 | 0.88 | MEP1A (0.53) | GSK3BMEP1AMEP1BALDH1A1CYP1A2 | |
| SCHEMBL9846008 | 0.87 | MMP12 (0.51) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1998639 | 0.87 | MMP3 (0.47) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL1840559 | 0.86 | MEP1A (0.51) | GSK3BMEP1AMEP1BALDH1A1MAOB | |
| SCHEMBL28747370 | 0.86 | CLK4 (0.46) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| Bromide SCHEMBL30583664 | 0.85 | MEP1A (0.50) | GSK3BMEP1AMEP1BALDH1A1CYP1A2 | |
| SCHEMBL7507668 | 0.84 | GSK3B (0.42) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7450600 | 0.83 | CLK4 (0.50) | CLK4GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2154026 | 0.82 | CLK4 (0.65) | CLK4GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1214291-A1 | BIPHENYL DERIVATIVES USED AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1200405-A1 | BENZENAMINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6380430-B1 | ANTICOAGULANTS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTERHAFTUNG (DE) | 2002-04-30 | — | — | US | disclosed |
| US-6350761-B1 | INHIBITORS OF THE ENZYME, FACTOR XA; | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| WO-2001021582-A1 | BIPHENYL DERIVATIVES USED AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-03-29 | — | — | WO | disclosed |
| EP-1076643-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-2001009093-A1 | BENZENAMINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-1999057096-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | CLK4 4041/4885GABRG2 34/4885GABRB3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.